Skip to content

News

ScaiVision® performs best-in-class at sample class prediction!

ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming all competitor algorithms.
Read More

Scailyte participates @ swissnex san francisco DEMO DAY!

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day. Scailyte will present its pioneering AI-based platform for biomarker discovery from single-cell and clinical data to enable precision diagnostics in oncology, immunology and women’s health. Scailyte’s forward-thinking team will explain how they plan to unlock clinically relevant insights which will improve patient outcomes.
Read More

Scailyte Q3 2020 Update

Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Read More

ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.

As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus, indications and presenting the biomarker portfolio.
Read More

Scailyte closed today their pre-series A financing with Investiere as an additional investor

Scailyte and CHU Rennes partnership for identifying Covid-19 patients May 18 2020 Scailyte™ is delighted to welcome investiere as an additional investor just before closing the pre-series A financing round.™
Read More
Making groundbreaking discoveries require collaborations and joint-ventures.